BioSpace News Archive

BioSpace’s 2022 Salary Report explores the average salaries and salary trends of life sciences professionals. Though movement in the labor market slowed during the pandemic, recovery has been swift and employers are once again having to cope with a highly competitive talent market.

While grappling with financial challenges, the biotech industry is forced to pivot to flexible business models.

The 2021 Salary Report is significant in more ways than one. This year, BioSpace analyzed salary data through two key lenses: the impact of the pandemic, and for the first time, race and ethnicity.

Masimo announced the findings of a prospective, randomized study published in Perioperative Medicine in which Dr. Yu Wang and colleagues at institutions in Shenzhen, Shaoguan, and Guangzhou, China evaluated the use of noninvasive, continuous Masimo PVi®, as part of goal-directed fluid therapy, to guide intraoperative fluid administration during gastrointestinal surgery on elderly patients by comparing it to conventional fluid therapy.

Abivax SA announced that it has concurrently signed two structured debt financing transactions for a total amount of up to EUR 150M consisting of up to EUR 75M from Kreos Capital and Claret European Growth Capital together with the issuance of warrants exercisable to receive up to EUR 8M worth of ordinary shares of the Company, par value of EUR 0.01 per share, and up to EUR 75M from a fund advised by Heights Capital Management, Inc..

IDEAYA Biosciences, Inc. announced the clearance of an Investigational New Drug application with the U.S. FDA for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101, a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of poly- polymerase, for the treatment of patients having tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency.

Aurinia Pharmaceuticals Inc. announced that its Board of Directors has appointed two new directors.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that a team of globally renowned researchers utilized two NanoString platforms, the nCounter® Analysis System and GeoMx® Digital Spatial Profiler, to decode the immune response following the transplantation of genetically modified pig kidneys into humans.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that Dan L. Dearen, president and chief financial officer, is retiring from the company.

Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.